Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Loargys Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentEmpire BluecrossPolicy CC-0301

    Loargys (pegzilarginase-nbln) Coverage Criteria

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0301 alerts

    Get alerted when Policy CC-0301 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity review for Loargys, an enzyme replacement therapy for adults and children 2 years of age or older with Arginase 1 Deficiency. Coverage requires diagnostic verification, concurrent dietary protein restriction, and additional response documentation for continuation therapy.

    Policy Summary
    PayerEmpire Bluecross
    PolicyLoargys (pegzilarginase-nbln) Coverage Criteria
    Policy CodePolicy CC-0301
    Change TypeNew policy
    Effective DateApr 22, 2026
    Last ReviewMar 9, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing eligible age, verified Arginase 1 Deficiency, dietary protein restriction, and required treatment response.
    SourceLink
    POLICY UPDATE CHANGES

    New clinical criteria were established for initial and continuation coverage of Loargys.

    A quantity limit was added for Loargys of 0.2 mg/kg once weekly.

    HCPCS codes C9399 and J3590 and ICD-10-CM code E72.21 were added for Loargys-related billing and diagnosis coding.

    Documentation requirements were added to support verification of Arginase 1 Deficiency.

    ≥2 yearsMinimum age for initial therapy
    >300 μmol/LPlasma arginine diagnostic threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    0.2 mg/kg weeklyQuantity limit
    3Accepted diagnostic verification pathways
    2Listed HCPCS billing codes

    Coverage Criteria

    Initial Therapy

    Initial requests may be approved when all of the following are met:

    ALL required criteria

    • Age: Individual is 2 years of age or older.≥2 years
    • Diagnosis: Individual has a diagnosis of Arginase 1 Deficiency (ARG1-D).
    • ONE accepted diagnostic verification method

      • ARG1 genetic testing: Genetic testing demonstrates a pathogenic mutation in the arginase 1 (ARG1) gene.
      • Enzyme activity: Arginase enzyme activity in erythrocytes is significantly decreased or absent.
      • Plasma arginine level is greater than 300 μmol/L.>300 μmol/L
    • Dietary protein restriction: Individual is using Loargys in combination with dietary protein restriction.

    Continuation Therapy

    Continuation requests may be approved when all of the following are met:

    ALL required criteria

    • Diagnosis: Individual has a diagnosis of Arginase 1 Deficiency (ARG1-D).
    • ONE accepted diagnostic verification method

      • ARG1 genetic testing: Genetic testing demonstrates a pathogenic mutation in the arginase 1 (ARG1) gene.
      • Enzyme activity: Arginase enzyme activity in erythrocytes is significantly decreased or absent.
      • Plasma arginine level is greater than 300 μmol/L.>300 μmol/L

    Loargys may not be approved for indications other than Arginase 1 Deficiency (ARG1-D).

    Loargys may not be approved when the applicable initial or continuation coverage criteria are not met.

    Coding Information

    HCPCSHCPCS
    C9399Unclassified drugs or biologicals [when specified as Loargys (pegzilarginase- nbln)]
    J3590Unclassified biologics [when specified as Loargys (pegzilarginase-nbln)]
    ICD-10 DiagnosisICD-10
    E72.21Argininemia [Arginase 1 deficiency]
    Plasma Arginine
    Diagnostic thresholdGreater than 300 μmol/L
    PurposeOne accepted method for verifying Arginase 1 Deficiency
    MeasurementPlasma arginine level
    Minimum Age
    Minimum age2 years or older
    Applies toInitial Loargys requests
    Covered populationAdult and pediatric individuals with Arginase 1 Deficiency

    Provider Actions and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for coverage of Loargys (pegzilarginase-nbln). Submit the request for clinical review with documentation supporting the applicable initial or continuation criteria.

    Documentation Required

    Diagnostic Verification

    Document a diagnosis of Arginase 1 Deficiency (ARG1-D) and verify the diagnosis through at least one accepted pathway.

    • Genetic testing demonstrating a pathogenic mutation in the arginase 1 (ARG1) gene.
    • Significantly decreased or absent arginase enzyme activity in erythrocytes.
    • Plasma arginine level greater than 300 μmol/L.

    Clinical Background

    Arginase 1 Deficiency is a rare inherited urea-cycle disorder caused by deficient arginase activity, resulting in persistently elevated plasma arginine and progressive neurological symptoms.

    Definitions

    Arginase 1 Deficiency (ARG1-D)
    ConditionRare inherited metabolic disorder
    Enzyme affectedArginase, an enzyme in the urea cycle
    Urea-cycle functionTransforms nitrogen for excretion from the body
    Clinical featuresPersistently high plasma arginine and progressive, severe neurological symptoms
    Hypersensitivity Reaction
    Reaction typeSerious, potentially life-threatening immune-mediated reaction
    IncludesAnaphylaxis

    Initial Therapy Criteria

    Initial Therapy

    Initial requests may be approved when all criteria are met:

    ALL required criteria

    • Age: Individual is 2 years of age or older.≥2 years
    • Diagnosis: Individual has a diagnosis of Arginase 1 Deficiency (ARG1-D).
    • ONE accepted diagnostic verification method

      • ARG1 genetic testing: Genetic testing demonstrates a pathogenic mutation in the arginase 1 (ARG1) gene.

    Continuation Therapy Criteria

    Continuation Therapy

    Continuation requests may be approved when all criteria are met:

    ALL required criteria

    • Diagnosis: Individual has a diagnosis of Arginase 1 Deficiency (ARG1-D).
    • ONE accepted diagnostic verification method

      • ARG1 genetic testing: Genetic testing demonstrates a pathogenic mutation in the arginase 1 (ARG1) gene.
      • Enzyme activity: Arginase enzyme activity in erythrocytes is significantly decreased or absent.

    Quantity Limits

    Quantity Limit
    DrugLoargys (pegzilarginase-nbln)
    Vial presentation2 mg/0.4 mL, 5 mg/mL vial
    Quantity limit0.2 mg/kg once weekly

    Site of Care

    Note

    Initiate Loargys in an equipped healthcare setting

    Initiate Loargys in a healthcare setting with appropriate monitoring and support measures, including access to cardiopulmonary resuscitation equipment.

    • Maintain appropriate monitoring during initiation.
    • Ensure support measures and cardiopulmonary resuscitation equipment are available.
    Policy Summary
    PayerEmpire Bluecross
    PolicyLoargys (pegzilarginase-nbln) Coverage Criteria
    Policy CodePolicy CC-0301
    Change TypeNew policy
    Effective DateApr 22, 2026
    Last ReviewMar 9, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing eligible age, verified Arginase 1 Deficiency, dietary protein restriction, and required treatment response.
    SourceLink
    On This Page
    Coverage CriteriaCoding InformationProvider Actions and DocumentationClinical BackgroundDefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaQuantity LimitsSite of Care
  1. Dietary protein restriction: Individual is using Loargys in combination with dietary protein restriction.
  2. Treatment response: Documentation shows a clinically significant reduction in plasma arginine levels while on Loargys therapy.Clinically significant reduction
  3. Documentation Required

    Dietary Restriction and Treatment Response

    Document that Loargys is being used in combination with dietary protein restriction. For continuation requests, also provide documentation of a clinically significant reduction in plasma arginine levels while on Loargys therapy.

    • Initial therapy: dietary protein restriction must be documented.
    • Continuation therapy: dietary protein restriction and clinically significant treatment response must be documented.
    Denial Risk

    Criteria or Indication Not Met

    Loargys may not be approved when the applicable coverage criteria are not met or when it is requested for an indication other than Arginase 1 Deficiency (ARG1-D).

    • Denial may apply when initial or continuation criteria are unmet.
    • All other indications are not covered under this policy.
    Denial Risk

    Initial Therapy Requirements

    Initial requests may be denied when required eligibility or documentation is missing, including the minimum age, ARG1-D diagnosis, accepted diagnostic verification, or use with dietary protein restriction.

    • Individual must be 2 years of age or older.
    • Diagnosis of Arginase 1 Deficiency (ARG1-D) is required.
    • Accepted diagnostic verification must be provided.
    • Use in combination with dietary protein restriction must be documented.
    Denial Risk

    Insufficient Continuation Response

    Continuation requests may be denied when documentation does not show a clinically significant reduction in plasma arginine levels while the individual is receiving Loargys therapy.

    • Document the clinically significant reduction in plasma arginine during treatment.
    • Continuation also requires ARG1-D, accepted diagnostic verification, and dietary protein restriction.
    TimingMay occur early in treatment or after prolonged therapy
    Associated therapyEnzyme replacement therapy, including Loargys
  4. Enzyme activity: Arginase enzyme activity in erythrocytes is significantly decreased or absent.
  5. Plasma arginine level is greater than 300 μmol/L.>300 μmol/L
  6. Dietary protein restriction: Individual is using Loargys in combination with dietary protein restriction.
  7. Plasma arginine level is greater than 300 μmol/L.>300 μmol/L
  8. Dietary protein restriction: Individual is using Loargys in combination with dietary protein restriction.
  9. Treatment response: Documentation shows a clinically significant reduction in plasma arginine levels while on Loargys therapy.Clinically significant reduction